Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Deschenes, Marc
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a	Completed	3	407	Europe, Canada, US, RoW	Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir	Eiger BioPharmaceuticals	Hepatitis Delta Virus	10/22	03/23
CaNAL, NCT03569826: Canadian Network for Autoimmune Liver Disease	Recruiting	N/A	2500	Canada	Observational; no intervention	University Health Network, Toronto	Primary Bilary Cirrhosis (PBC), Autoimmune Hepatitis, Overlap Syndrome	12/28	12/28